Please login to the form below

Not currently logged in
Email:
Password:

Crohn's disease drug maintains remission

Abbott's Humira is first anti-TNF in the EU with long-term Crohn's data included in its label

Data from open label studies has demonstrated that treatment with Abbott's Humira (adalimumab) provides sustained remission for up to three years in patients with moderate-to-severe Crohn's disease. The majority of patients treated with adalimumab, who were in remission at one year, remained in remission after two additional years. The latest three-year sustained remission data is now included in the Humira label for EU countries.

Crohn's disease is a chronic inflammatory disease of the intestines and affects nearly 60,000 people in the UK. Earlier this year, adalimumab was recommended by the UK's National Institute for Health and Clinical Excellence (NICE) for the treatment of adults with severe and active Crohn's disease whose disease has not responded to conventional therapy, or who are intolerant of, or have contraindications to, conventional therapy. It is also the first anti-TNF therapy, in a pen delivery system, to be appraised by NICE for Crohn's disease.

"Crohn's is a chronic and devastating condition and patients require a therapy that not only brings their disease under control, but also keeps it that way," said Dr James Lindsay, consultant gastroenterologist at the Barts and the London NHS Trust. "This three-year efficacy data offers increased confidence to clinicians who may be prescribing adalimumab for their Crohn's patients."

The results for the three-year sustained remission are from the open label studies, ADHERE and CLASSIC II. A total of 272 patients from ADHERE and 117 patients from CLASSIC II were followed for at least three years of open-label adalimumab treatment. Results show that almost 70 per cent of patients in ADHERE and just over 75 per cent of patients in CLASSIC II continued to be in clinical remission after three years of open-label treatment. Clinical response was also maintained in over 85 per cent and over 87 per cent of patients, respectively.

Abbott also offers a package of personalised services for patients with Crohn's disease on adalimumab and supports gastroenterology clinics that see Crohn's patients.

24th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics